文献速递血栓与止血

Wiskott-Aldrich综合征患者巨核细胞加速死亡

Accelerated death of megakaryocytes from Wiskott-Aldrich syndrome patients.
PubMed 文献 · Br J Haematol · 2023-05-23

本研究比较了32例Wiskott-Aldrich综合征(WAS)患者与17例健康供者的骨髓巨核细胞(MK)活力和形态,发现WAS患者MK成熟阶段分布异常、磷脂酰丝氨酸外化比例升高,且与突变类型和疾病评分相关,提示MK死亡增加和成熟改变可能参与WAS血小板减少。

要点

  • WAS患者巨核细胞成熟阶段3比例为40±22%,正常对照为23±11%(p=0.02)。
  • WAS患者巨核细胞磷脂酰丝氨酸阳性比例为21±21%,健康对照为2±4%(p<0.01)。
  • 截短突变和较高疾病评分与磷脂酰丝氨酸阳性巨核细胞比例呈正相关(Spearman r=0.6,p<0.003)。

核心结论

  • WAS患者巨核细胞死亡倾向增加且成熟模式改变,两者均可能参与WAS患者血小板减少的发生。

研究设计与样本

  • 研究纳入32例WAS患者和17例健康供者,比较未治疗及罗米司亭治疗的WAS患者与正常对照的巨核细胞活力和形态。
  • 巨核细胞通过表面固定化抗GPIIb-IIIa抗体从骨髓穿刺液中捕获,用光学显微镜测定磷脂酰丝氨酸外化、成熟阶段分布和大小。

主要发现

  • WAS患者巨核细胞成熟阶段分布与对照不同:成熟阶段3比例为40±22%,正常对照为23±11%(p=0.02)。
  • WAS患者巨核母细胞形态比例为24±20%,正常对照为39±14%(p=0.05)。
  • 罗米司亭治疗使巨核细胞成熟阶段分布接近正常。
  • WAS患者磷脂酰丝氨酸阳性巨核细胞比例为21±21%,显著高于健康对照的2±4%(p<0.01)。
  • 具有更多破坏性截短突变和较高疾病评分的WAS患者,磷脂酰丝氨酸阳性巨核细胞比例更高(Spearman r=0.6,p<0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Wiskott-Aldrich syndrome (WAS) is an X-linked recessive disorder caused by WAS gene mutations resulting in haematopoietic/immune cell defects. Recent studies report accelerated death of WAS platelets and lymphocytes. Data on megakaryocyte (MK) maturation, viability and their possible role in thrombocytopenia development in WAS are limited. In this study we evaluate the MK viability and morphology in untreated, romiplostim-treated WAS patients compared with normal controls. The study included 32 WAS patients and 17 healthy donors. MKs were captured from bone marrow aspirates by surface-immobilized anti-GPIIb-IIIa antibody. Viability (by phosphatidylserine [PS] externalization), distribution by maturation stages and size of MK were determined by light microscopy. MK distribution by maturation stages in patients differed from controls. 40 ± 22% of WAS MKs versus 23 ± 11% of normal MKs were at maturation stage 3 (p = 0.02), whereas 24 ± 20% in WAS and 39 ± 14% in controls had megakaryoblast morphology (p = 0.05). Romiplostim treatment changed the MK maturation stages distribution close to normal. PS-positive (PS+) MK in WAS was significantly higher (21 ± 21%) than in healthy controls (2 ± 4%, p < 0.01). WAS patients with more damaging truncating mutations and higher disease score had higher PS+ MK fraction (Spearman r = 0.6, p < 0.003). We conclude that WAS MKs have increased cell death tendency and changes in maturation pattern. Both could contribute to thrombocytopenia in WAS patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Obydennyi SI, Kuznetsova SA, Fedyanina OS, et al. Accelerated death of megakaryocytes from Wiskott-Aldrich syndrome patients. Br J Haematol. 2023. PMID: 37221654. doi:10.1111/bjh.18875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。